Amgen Announces Robust Weight Loss With Maritide In People Living With Obesity Or Overweight At 52 Weeks In A Phase 2 Study
MariTide Demonstrated up to ~20% Average Weight Loss at 52 [...]
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
– Attruby is the first and only approved product with a [...]
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Acoramidis demonstrated the earliest known time to separation in cardiovascular [...]
Promoting Cardiovascular Health Equity Association of Black Cardiologists Practical Model for Community-Engaged
Despite advancements in the assessment and treatment of cardiovascular disease [...]
Improving Health Care Access and Outcomes for Minority and High-Risk Populations
The Association of Black Cardiologists (ABC) convened a roundtable [...]
Nurturing Diverse Generations of the Medical Workforce for Success With Authenticity: An Association of Black Cardiologists’ Roundtable
The COVID-19 pandemic exposed the consequences of systemic racism in [...]